In another Phase 3 study, the PFS of gefitinib alone in newly diagnosed metastatic NSCLC with EGFR mutation was only 11.9 months with the objective response rate (ORR) being 67%, while in the combination group where patients were treated with gefitinib combined with carboplatin plus pemetrexed, ORR was 84% and PFS nearly doubled (20.9 months) (9). This evidence concerns the gene EGFR and non-small cell lung carcinoma.